EMA Wants More Staff For Continuing Pandemic Workload
Agency Expects 11 COVID-19-Related Product Applications This Year
Executive Summary
The more products the European Medicines Agency approves, the more post-authorization applications it receives, leading to an ever-growing spiral in its workload. This, together with the increase in COVID-19-related tasks, new responsibilities in clinical trials and other areas, and a decline in staff numbers over the years, is posing some real resource issues at the agency.
You may also be interested in...
As EMA Chair, Ireland's Nolan Pledges Agility, Responsiveness, Solidarity In Turbulent Times
Lorraine Nolan has become chair of the European Medicines Agency’s management board.
New EMA Chair Pledges Agility, Responsiveness & Solidarity In Turbulent Times
Lorraine Nolan has become the new chair of the European Medicines Agency’s management board.
New EU Bodies To Monitor Drug Supply In Health Crises
New pandemic-related responsibilities have been entrusted to the European Medicines Agency by a regulation published on 31 January. They include coordinating vaccine safety and effectiveness studies and setting up a European network of real-world data to help support health crisis preparedness and response.